Press Releases2017-09-13T20:17:34+00:00

Press Releases

US Gastroenterologists Report VARSITY Trial Data and JAK Inhibitor Safety Concerns Will Impact Their Prescribing Behavior in Ulcerative Colitis, with Potential Implications for Crohn’s Treatment

Takeda’s Phase 3b head-to-head study comparing Entyvio to AbbVie’s Humira, as well as preliminary results of an ongoing post-marketing requirement study for Pfizer’s Xeljanz regarding safety are beginning to affect gastroenterologists’ perceptions and use of key brands for the treatment of inflammatory bowel disease. Download Report Overview EXTON, Pa., June 5, 2019 /PRNewswire/ — While both the ulcerative colitis (UC) and Crohn’s disease markets have remained relatively stable since the prior quarter in terms of brand share and user base, Spherix captured reactions to recent key market events that could begin to ripple through the landscape (particularly in UC). According to [...]

June 5, 2019|

EMD Serono’s Mavenclad Edges Past Novartis’ Gilenya in the Recent Switch Segment of Canada’s Multiple Sclerosis Market, Although Brand Familiarity Remains An Addressable Barrier

Even with the recent favorable conclusion to pan-Canadian Pharmaceutical Alliance negotiations, the prescriber base for Roche’s Ocrevus may be nearing a plateau requiring existing prescribers to fuel the majority of anticipated brand growth, according to the inaugural Canada report from Spherix Global Insights Download Report Overview EXTON, Pa., May 28, 2019 ― Therapeutic choice for multiple sclerosis (MS) in Canada has expanded substantially over the past two years with Health Canada’s November 2017 approval of EMD Serono’s Mavenclad for relapsing-remitting MS (RRMS) and August 2017 and February 2018 approvals of Roche’s Ocrevus for RRMS and early primary progressive MS (PPMS), [...]

May 28, 2019|

US Dermatologists Report a Sizeable Portion of Their Atopic Dermatitis Patients Currently Treated with Sanofi/Regeneron’s Dupixent Would be Switched to Another Targeted Therapy if Available

According to a recent study conducted by Spherix Global Insights, Dupixent continues to be well-received amongst US dermatologists, though overall use will likely take a hit once new advance systemic treatments become available. Download Report Overview EXTON, Pa., May 15, 2019 /PRNewswire/ —In Spherix’s second quarter update of RealTime Dynamix™: Atopic Dermatitis (US), Sanofi/Regeneron’s Dupixent continues to grow two years post-launch, with the near totality of US dermatologists (n=100) reporting use of the brand and the majority prescribing the agent to more than five atopic dermatitis (AD) patients. Collaborating dermatologists indicate that the first biologic to treat moderate-to-severe AD has [...]

May 14, 2019|

Biogen’s Tecfidera Share of the Multiple Sclerosis Switch Segment Continues a Three-Year Downward Trend to the Benefit of Novartis’ Gilenya and Genentech’s Ocrevus

EMD Serono and Novartis will have the greatest opportunity to drive patient switches to Mavenclad and Mayzent, respectively, within the first six months following transition to secondary progressive multiple sclerosis, according to a new audit by Spherix Global Insights Download Report Overview EXTON, Pa., April 29, 2019 ― According to Spherix’s new RealWorld Dynamix™: DMT Switching in Multiple Sclerosis (US) audit, more than half of multiple sclerosis (MS) patients (n=1,003) recently switched to a new disease-modifying therapy (DMT) were prescribed one of four brands ― Genentech’s Ocrevus, Biogen’s Tecfidera, Novartis’ Gilenya, or Teva’s Copaxone. Among the oral DMTs, Tecfidera just [...]

April 29, 2019|

In Psoriasis, Use of the IL-17 Inhibitors, Novartis’ Cosentyx and Eli Lilly’s Taltz, are Neck and Neck, but the Former Still Holds a Significant First-to-Market Edge Amongst Rheumatologists for the Treatment of Psoriatic Arthritis, According to Data Recently Collected by Spherix Global Insights

After several years on the market, the majority of US dermatologists report that Cosentyx has lost its advantage over Taltz as the first IL-17 inhibitor on the market; with increased penetration of Taltz for the treatment of psoriatic arthritis, will rheumatologists follow suit? Download Report Overview EXTON, Pa., April 17, 2019 /PRNewswire/ — Spherix Global Insights has been tracking the evolution of the US psoriatic arthritis (PsA) market on a quarterly basis since 2015 via the RealTime Dynamix™: Psoriatic Arthritis (US) report series. The PsA landscape has been experiencing large-scale change as rheumatologists continue to adopt alternate mechanism of action (MOA) [...]

April 18, 2019|

Preferential First-Line Use of Biogen’s Tecfidera and Continued Uptake of Merck KGaA’s Mavenclad Drives the Significant Increase in Oral Disease-Modifying Therapy Class Share in the European Multiple Sclerosis Market Over the Past Year

Assuming approval and dependent upon the label in Europe, Novartis’ Mayzent should be well positioned for strong adoption in active secondary progressive multiple sclerosis and transitioning relapsing-remitting multiple sclerosis, although low unaided awareness of the latter patient type may hamper uptake without a focused educational strategy, according to the prelaunch assessment in a new report from Spherix Global Insights Download Report Overview EXTON, Pa., April 10, 2019 ―Self-reported oral disease-modifying therapy (DMT) class share has increased significantly over the past year in the EU multiple sclerosis (MS) market, pulling share from the injectable DMT classes. In the current wave of [...]

April 10, 2019|